Haymarket Media, a global media company, has announced its acquisition of the American Journal of Endocannabinoid Medicine (AJEM), a peer-reviewed journal focused on cannabinoid medicine. The move is part of Haymarket’s strategy to provide healthcare professionals (HCPs) with high-quality, peer-reviewed content on cannabinoid-based therapy.
AJEM, founded and launched in 2019 by Ken Watkins, fills a knowledge gap in the medical community by offering widespread access to trusted, peer-reviewed content on cannabinoid-based medicine. Physicians are not trained in the endocannabinoid system (ECS) in medical school, yet they are increasingly caring for patients using cannabinoid-based medicine, often in conjunction with other pharmaceuticals.
AJEM will benefit from Haymarket’s digital expertise in delivering relevant and timely clinical content to a broad audience of HCPs. The journal will also join the Haymarket Medical Network (HMN), which reaches healthcare practitioners through a multichannel environment with more than 20 unique brands offered across multiple formats, including web, app, print, and live events.
Overall, the acquisition of AJEM by Haymarket Media is a significant move towards providing the medical community with high-quality and trusted content on cannabinoid-based therapy, and it reinforces Haymarket’s commitment to educating physicians in this emerging therapeutic area.
Click here to read the original press release.
